| 0.474 -0.01 (-2.07%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.84 |
1-year : | 1.03 |
| Resists | First : | 0.72 |
Second : | 0.88 |
| Pivot price | 0.51 |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.53 |
| MA(100) : | 0.72 |
MA(250) : | 0.95 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 13.4 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 2.14 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RDHL ] has closed above bottom band by 21.7%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.5 |
| Low: | 0.46 - 0.47 | 0.47 - 0.47 |
| Close: | 0.47 - 0.47 | 0.47 - 0.48 |
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Wed, 07 Oct 2026
Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle - Stock Titan
Wed, 30 Sep 2026
Redhill Biopharma Ltd (NASDAQ: RDHL) Share Price, RDHL Stock News, RDHL Share Price & Updates - kalkine.ca
Wed, 30 Sep 2026
Continuing-operations revenue fell to zero at RedHill Biopharma (RDHL), while its first-half loss widened. - Stock Titan
Wed, 30 Sep 2026
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results - PR Newswire
Thu, 10 Sep 2026
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties? - Yahoo Finance
Mon, 31 Aug 2026
RedHill Biopharma Shares Surge as Talicia Sale to Apotex Brings $18 Million Upfront - finance.biggo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.2e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.79e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -150 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 765.3 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 286000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 57777.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.79 |
| Dividend | 0 |
| Forward Dividend | 14710 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|